Published On : July 2026
Diagnosing an infectious disease accurately depends on choosing the right testing approach for the pathogen, the clinical urgency, and the setting where the sample is collected. Infectious disease in vitro diagnostics span two complementary segmentation lenses: the physical testing platform, such as ELISA, CLIA, rapid diagnostic tests, PCR, multiplex molecular panels, or point-of-care kits, and the underlying test method, such as serology, molecular, antigen-based, or culture-based detection.
These two lenses interact constantly in real laboratory workflows. A single platform, PCR for instance, is itself a molecular test method, while a rapid diagnostic test typically performs antigen-based detection in a lateral-flow format. This platform-and-method structure sits within the global infectious disease IVD market outlook, which tracks how these testing technologies are adopted across regions, disease areas, and customer segments. Understanding both dimensions together explains why laboratories often run more than one type of test on the same patient sample, layering a fast screening method with a slower, more definitive confirmatory one.
ELISA, or enzyme-linked immunosorbent assay, remains one of the most established testing platforms in infectious disease diagnostics. The method works by binding a target antigen or antibody to an enzyme-linked detection reagent, producing a color change that is measured optically to indicate a positive or negative result. Its strengths are cost efficiency and proven reliability at scale, which is why it remains the default screening method for many blood bank and public health surveillance programs despite the emergence of newer platforms.
CLIA, or chemiluminescence immunoassay, builds on the same antigen-antibody binding principle but replaces the colorimetric enzyme reaction with a light-emitting chemical reaction, measured by a luminometer. This substitution delivers meaningfully higher sensitivity and a wider dynamic range than traditional ELISA, and CLIA platforms are typically automated end to end, which is why hospital and reference laboratories running high sample volumes have gravitated toward them for routine serology testing.
Rapid diagnostic tests, or RDTs, take a different design philosophy entirely. Rather than optimizing for laboratory throughput, RDTs are built for speed and simplicity, typically using a lateral-flow immunochromatographic strip that produces a visually readable result within 15 to 30 minutes without any instrumentation. This makes RDTs the platform of choice in resource-limited settings, emergency departments, and outbreak-response scenarios where waiting for a batch-run laboratory result is not clinically acceptable.
Each of these three platforms occupies a distinct niche, positioned along a spectrum from lowest cost and simplest infrastructure requirement, RDTs, through mid-throughput automated serology, ELISA and CLIA. It is rare for one platform to fully displace another because the underlying use cases differ so substantially.
Polymerase chain reaction, or PCR, and its reverse-transcription variant, RT-PCR, detect a pathogen's genetic material directly rather than the antibody or antigen response to it. By amplifying tiny quantities of DNA or RNA through repeated thermal cycling, PCR-based tests can detect an active infection days before an antibody response would even be measurable, which is why they remain the diagnostic gold standard for viral load monitoring, early-stage infection detection, and genotyping applications such as hepatitis strain identification.
Multiplex molecular panels extend this same amplification principle to detect multiple pathogens simultaneously from a single sample, using differently labeled probes or sequencing-based readouts to distinguish targets within one reaction. Instead of ordering several separate respiratory or gastrointestinal pathogen tests individually, a laboratory can run one multiplex panel and receive a complete pathogen profile in a single turnaround cycle. This consolidation is particularly valuable for disease-specific multiplex panels used in respiratory, gastrointestinal, and sexually transmitted infection testing, where clinicians frequently need to distinguish between pathogens presenting with overlapping symptoms.
The tradeoff is cost and infrastructure. Molecular platforms require thermal cyclers or automated extraction-and-amplification instruments, along with technical staff trained to interpret amplification curves, making them better suited to central and reference laboratories than to fully decentralized settings. Even so, adoption continues to expand as instrument costs decline and manufacturers introduce more compact benchtop molecular systems designed for smaller hospital laboratories.
Point-of-care testing kits are designed to deliver a result at or near the location where the patient is being seen, whether that is a clinic, pharmacy, ambulance, or remote health post, rather than requiring sample transport to a central laboratory. Many point-of-care kits use rapid antigen or lateral-flow formats, though a growing number now incorporate compact molecular cartridges that bring PCR-level sensitivity into a near-patient device.
The clinical value of point-of-care testing lies in closing the gap between sample collection and clinical decision-making. A clinician who can confirm an infectious disease diagnosis within the same visit can begin appropriate treatment or isolation precautions immediately, rather than waiting for a result that arrives after the patient has already left. This immediacy is reshaping point-of-care adoption across care settings, particularly outside traditional hospital and reference laboratory environments.
The tradeoff for this convenience is typically a narrower test menu and, for antigen-based point-of-care formats specifically, somewhat lower sensitivity compared with laboratory-based molecular testing. This is why point-of-care results are often used for triage and initial management decisions while laboratory confirmation follows for select cases.
Choosing among serology, molecular, antigen-based, and culture-based testing methods comes down to balancing turnaround time against sensitivity and the setting where the test will be performed. The comparison below summarizes typical characteristics of each method at a qualitative level.
|
Test Method |
Typical Turnaround |
Typical Sensitivity / Specificity Profile |
Typical Setting of Use |
|
Serology |
Same day to 24 hours |
Strong specificity; sensitivity depends on timing of antibody response |
Central labs, blood banks, surveillance |
|
Molecular |
Hours to same day |
High sensitivity and specificity; reference standard for many pathogens |
Central and reference labs, hospital labs |
|
Antigen-Based |
15 to 30 minutes |
High specificity; sensitivity varies by pathogen load |
Point-of-care, urgent care, decentralized settings |
|
Culture-Based |
1 to several days |
Definitive confirmatory method; enables susceptibility testing |
Reference labs, hospital microbiology labs |
No single method wins outright. Laboratories typically layer methods, using a fast antigen or serology screen at the front end and reserving molecular or culture-based confirmation for cases where clinical stakes or ambiguous initial results demand a more definitive answer.
Three technology trends are reshaping how infectious disease testing platforms are designed and deployed. Multiplexing, the consolidation of multiple pathogen targets into a single test run, is expanding beyond respiratory and gastrointestinal panels into broader syndromic testing menus that cover dozens of possible pathogens from one sample.
Automation is compressing the labor and turnaround-time burden of high-volume immunoassay and molecular testing, with newer platforms integrating sample preparation, amplification, and result reporting into a single walk-away workflow that reduces the technician hours required per test.
Digital and AI-assisted diagnostics represent the newest frontier, using computer vision and machine learning to interpret lateral-flow test lines, flag ambiguous results for confirmatory testing, and support decentralized readers who may lack extensive laboratory training. Much of this innovation is concentrated among leading molecular diagnostics manufacturers that have made automation and multiplexing central to their product roadmaps.
Together, these trends are gradually shifting infectious disease testing away from single-target, single-platform workflows toward integrated systems capable of adapting to whichever pathogen or outbreak scenario a laboratory needs to address next.
What is the difference between PCR testing and rapid antigen testing?
PCR detects a pathogen's genetic material through amplification and offers very high sensitivity, typically requiring laboratory instrumentation and a turnaround measured in hours. Rapid antigen testing detects pathogen surface proteins directly, delivering results in 15 to 30 minutes without lab equipment, though generally with somewhat lower sensitivity at low pathogen loads.
What is a multiplex molecular panel and why is it used?
A multiplex molecular panel screens for multiple pathogens simultaneously in a single test run, using differently labeled probes to distinguish targets. It speeds up diagnosis and reduces sample and reagent use when a patient's symptoms could be caused by several possible pathogens.
Is ELISA still used for infectious disease diagnosis?
Yes. ELISA remains widely used for infectious disease serology, particularly in blood bank screening and large-scale public health surveillance, due to its cost efficiency and proven reliability, even as newer automated immunoassay and molecular platforms have expanded testing options.
How does point-of-care testing accuracy compare to central laboratory testing?
Point-of-care tests, particularly antigen-based formats, generally offer somewhat lower sensitivity than central laboratory molecular testing, though newer point-of-care molecular cartridges are narrowing that gap. The tradeoff is speed, since results are available within minutes rather than hours.